S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
NASDAQ:ABVX

ABIVAX Société Anonyme (ABVX) Stock Price, News & Analysis

$15.11
+0.23 (+1.55%)
(As of 04/18/2024 ET)
Today's Range
$14.76
$15.24
50-Day Range
$11.99
$15.39
52-Week Range
$7.99
$17.02
Volume
6,763 shs
Average Volume
109,118 shs
Market Capitalization
$950.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

ABIVAX Société Anonyme MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
19.1% Upside
$18.00 Price Target
Short Interest
Healthy
0.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.87mentions of ABIVAX Société Anonyme in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.40) to ($2.88) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.81 out of 5 stars

Medical Sector

832nd out of 918 stocks

Pharmaceutical Preparations Industry

368th out of 402 stocks

ABVX stock logo

About ABIVAX Société Anonyme Stock (NASDAQ:ABVX)

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

ABVX Stock Price History

ABVX Stock News Headlines

ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Update
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
ABIVAX Société Anonyme (NASDAQ:ABVX) PT Raised to $16.00
ABVX ABIVAX Société Anonyme
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Abivax SA ADR ABVX
Abivax S.A. ADR
ABIVAX Société Anonyme (ABVX.PA)
Abivax SA ABVX
See More Headlines
Receive ABVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ABIVAX Société Anonyme and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/18/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ABVX
Previous Symbol
NASDAQ:ABVX
Fax
N/A
Employees
61
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.00
High Stock Price Target
$20.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+19.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$950.87 million
Optionable
Not Optionable
Beta
N/A
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Marc M. P. de Garidel M.B.A. (Age 66)
    CEO & Interim Chair of Board
    Comp: $843.59k
  • Dr. Philippe Pouletty M.D. (Age 66)
    Ph.D., Founder & Director
  • Mr. Didier Blondel (Age 60)
    EVP, CFO & Board Secretary
  • Mr. Didier Scherrer Ph.D. (Age 54)
    Chief Scientific Officer
  • Mr. Patrick Malloy
    Senior Vice President of Investor Relations
  • Ms. Ida Hatoum (Age 49)
    Chief People Officer
  • Mr. Pierre Courteille M.B.A. (Age 55)
    Chief Business Officer
  • Mr. Jérôme Denis
    Executive Vice President of Process Development & Manufacturing
  • Mr. Sheldon Sloan M.D. (Age 65)
    Chief Medical Officer
  • Mr. Michael Ferguson B.S. (Age 46)
    M.B.A., Chief Commercial Officer

ABVX Stock Analysis - Frequently Asked Questions

Should I buy or sell ABIVAX Société Anonyme stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ABIVAX Société Anonyme in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABVX shares.
View ABVX analyst ratings
or view top-rated stocks.

What is ABIVAX Société Anonyme's stock price target for 2024?

3 analysts have issued twelve-month price objectives for ABIVAX Société Anonyme's stock. Their ABVX share price targets range from $16.00 to $20.00. On average, they predict the company's stock price to reach $18.00 in the next year. This suggests a possible upside of 19.1% from the stock's current price.
View analysts price targets for ABVX
or view top-rated stocks among Wall Street analysts.

How have ABVX shares performed in 2024?

ABIVAX Société Anonyme's stock was trading at $10.70 at the beginning of 2024. Since then, ABVX stock has increased by 41.2% and is now trading at $15.11.
View the best growth stocks for 2024 here
.

Are investors shorting ABIVAX Société Anonyme?

ABIVAX Société Anonyme saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 161,500 shares, an increase of 12.9% from the March 15th total of 143,000 shares. Based on an average daily volume of 113,600 shares, the short-interest ratio is presently 1.4 days. Approximately 0.3% of the shares of the company are sold short.
View ABIVAX Société Anonyme's Short Interest
.

When did ABIVAX Société Anonyme IPO?

ABIVAX Société Anonyme (ABVX) raised $217 million in an initial public offering (IPO) on Friday, October 20th 2023. The company issued 18,699,460 shares at $11.60 per share.

When did the company's lock-up period expire?

ABIVAX Société Anonyme's lock-up period expired on Wednesday, April 17th. ABIVAX Société Anonyme had issued 18,699,460 shares in its public offering on October 20th. The total size of the offering was $216,913,736 based on an initial share price of $11.60. Since the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

How do I buy shares of ABIVAX Société Anonyme?

Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABVX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners